An arbitrator has determined Prime Therapeutics violated federal and state antitrust laws against the AIDS Healthcare Foundation (AHF) and independent pharmacies. | Prime Therapeutics, a PBM owned by Blue Cross plans,

Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" prescription price hikes of 1,000% or more.

Even as a move to regulate pharmacy benefit managers like Express Scripts gets bipartisan support in Congress, a Missouri effort faces an uphill battle in part due to intense pressure from industry lobbyists.

Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

Oklahoma's attorney general has accused CVS's Caremark pharmacy benefit manager unit of under-reimbursing pharmacies for prescription drugs.

Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the controversial drug middlemen as the agency’s first report released last summer — but relies on more data.

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average acquisition cost for dozens of specialty generic drugs, bringing in more than $7.

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, OptumRx and Express Scripts.

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

FTC said the "Big 3 PBMs" — CVS’s Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx — imposed markups of hundreds to thousands of percent on critical drugs, including those ...